Exagen Inc. revised revenue guidance for the first quarter of 2023. The company provided first quarter of 2023 revenue guidance of $8.2 million to $9.2 million. The strong momentum seen in fourth quarter of 2022 have continued and the company increasing revenue guidance to a range of $9.2 million to $9.7 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.82 USD | -1.62% |
|
-7.14% | -8.54% |
05-14 | Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating | MT |
05-13 | Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.54% | 31.62M | |
+18.69% | 84.15B | |
-25.20% | 74.14B | |
+1.06% | 26.92B | |
-10.46% | 17.15B | |
-0.68% | 16.83B | |
-0.73% | 15.21B | |
+72.88% | 13.3B | |
+76.04% | 12.99B | |
-25.79% | 12.79B |
- Stock Market
- Equities
- XGN Stock
- News Exagen Inc.
- Exagen Inc. Revises Revenue Guidance For the First Quarter of 2023